[go: up one dir, main page]

HUS2200017I1 - Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére - Google Patents

Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére

Info

Publication number
HUS2200017I1
HUS2200017I1 HUS2200017C HUS2200017C HUS2200017I1 HU S2200017 I1 HUS2200017 I1 HU S2200017I1 HU S2200017 C HUS2200017 C HU S2200017C HU S2200017 C HUS2200017 C HU S2200017C HU S2200017 I1 HUS2200017 I1 HU S2200017I1
Authority
HU
Hungary
Prior art keywords
dihydronaphthyridines
treatment
kinase inhibitors
compounds useful
related compounds
Prior art date
Application number
HUS2200017C
Other languages
English (en)
Original Assignee
Deciphera Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deciphera Pharmaceuticals Llc filed Critical Deciphera Pharmaceuticals Llc
Publication of HUS2200017I1 publication Critical patent/HUS2200017I1/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
HUS2200017C 2012-06-07 2022-05-09 Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére HUS2200017I1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17208408.9A EP3366293B1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
PCT/US2012/041378 WO2013184119A1 (en) 2012-06-07 2012-06-07 Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
HUS2200017I1 true HUS2200017I1 (hu) 2022-06-28

Family

ID=49712374

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17208408A HUE049958T2 (hu) 2012-06-07 2012-06-07 Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HUS2200017C HUS2200017I1 (hu) 2012-06-07 2022-05-09 Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17208408A HUE049958T2 (hu) 2012-06-07 2012-06-07 Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére

Country Status (28)

Country Link
EP (3) EP3366293B1 (hu)
JP (1) JP5883195B2 (hu)
KR (1) KR101652229B1 (hu)
CN (3) CN110433162A (hu)
AU (1) AU2012327210B2 (hu)
BR (1) BR112014030577B1 (hu)
CA (1) CA2875970C (hu)
CY (1) CY1123377T1 (hu)
DK (2) DK3366293T3 (hu)
ES (2) ES2663605T3 (hu)
FR (1) FR22C1013I2 (hu)
HK (1) HK1209345A1 (hu)
HR (1) HRP20200864T1 (hu)
HU (2) HUE049958T2 (hu)
IL (1) IL236110A (hu)
LT (2) LT3366293T (hu)
LU (1) LUC00253I2 (hu)
MX (2) MX372814B (hu)
NO (1) NO2022010I1 (hu)
PH (2) PH12018502294B1 (hu)
PL (1) PL3366293T3 (hu)
PT (2) PT2858646T (hu)
RS (1) RS60406B1 (hu)
RU (1) RU2664055C2 (hu)
SG (1) SG11201408133TA (hu)
SI (1) SI3366293T1 (hu)
SM (1) SMT202000302T1 (hu)
WO (1) WO2013184119A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US9321786B2 (en) 2013-03-15 2016-04-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2892423T3 (es) 2013-03-15 2022-02-04 Celgene Car Llc Compuestos de heteroarilo y usos de los mismos
EP2968337B1 (en) 2013-03-15 2021-07-21 Celgene CAR LLC Heteroaryl compounds and uses thereof
SI3402792T1 (sl) * 2016-01-11 2022-01-31 Merck Patent Gmbh Derivati kinolin-2-ona
EA201992805A1 (ru) * 2017-05-30 2020-05-15 ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Применение 1-[4-бром-5-[1-этил-7-(метиламино)-2-оксо-1,2-дигидро-1,6-нафтиридин-3-ил]-2-фторфенил]-3-фенилмочевины и аналогов для лечения видов рака, связанных с генетическими нарушениями в рецепторе альфа тромбоцитарного фактора роста
WO2019056990A1 (zh) * 2017-09-20 2019-03-28 浙江海正药业股份有限公司 1,2-二氢-1,6-萘啶类衍生物、其制备方法及其在医药上的用途
WO2019152719A1 (en) 2018-01-31 2019-08-08 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2019152711A1 (en) 2018-01-31 2019-08-08 Diciphera Pharmaceuticals Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
WO2020185812A1 (en) * 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
CA3138300A1 (en) 2019-05-03 2020-11-12 Kinnate Biopharma Inc. Inhibitors of raf kinases
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
CA3150433A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
KR20220104702A (ko) 2019-10-24 2022-07-26 킨네이트 바이오파마 인크. Raf 키나제의 억제제
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
KR102535840B1 (ko) * 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN112625038A (zh) * 2020-12-31 2021-04-09 武汉九州钰民医药科技有限公司 制备瑞普替尼的方法
WO2022162690A1 (en) * 2021-01-28 2022-08-04 Dr. Reddy's Laboratories Limited Process for the preparation of ripretinib and solid state forms thereof
CA3216104A1 (en) 2021-04-23 2022-10-27 Aleksandra Franovic Treatment of cancer with a raf inhibitor
EP4476218A1 (en) * 2021-12-24 2024-12-18 Assia Chemical Industries Ltd. Improved processes for the preparation of ripretinib
CN114213411B (zh) * 2022-01-24 2023-06-30 成都伊诺达博医药科技有限公司 一种瑞普替尼的合成方法
WO2023150681A1 (en) 2022-02-03 2023-08-10 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1673343A4 (en) * 2003-10-08 2008-09-10 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
DE102006030524A1 (de) * 2006-07-01 2008-01-03 Koch Transporttechnik Gmbh Verfahren und Vorrichtung zur Beseitigung von lockerem Material auf wellenförmigen Oberflächen gestampfter Kohle für die Verkokung
CN101516379A (zh) * 2006-09-14 2009-08-26 迪赛孚尔制药有限公司 可用于治疗增殖性疾病的激酶抑制剂
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CN101528744A (zh) * 2006-10-20 2009-09-09 Irm责任有限公司 用于调节c-kit和pdgfr受体的组合物和方法
CL2009000400A1 (es) * 2008-02-22 2010-09-10 Irm Llc Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras.

Also Published As

Publication number Publication date
MX2014015024A (es) 2015-07-06
PH12018502294B1 (en) 2024-02-28
PT2858646T (pt) 2018-03-27
NO2022010I1 (no) 2022-04-07
SMT202000302T1 (it) 2020-07-08
ES2663605T3 (es) 2018-04-16
HK1209345A1 (en) 2016-04-01
CA2875970C (en) 2017-07-04
RU2014153920A (ru) 2016-07-27
HRP20200864T1 (hr) 2020-08-21
CN110403938A (zh) 2019-11-05
EP2858646A1 (en) 2015-04-15
EP3366293B1 (en) 2020-03-11
SI3366293T1 (sl) 2020-08-31
FR22C1013I1 (fr) 2022-06-17
DK3366293T3 (da) 2020-06-15
SG11201408133TA (en) 2015-01-29
PL3366293T3 (pl) 2020-09-21
FR22C1013I2 (fr) 2022-12-30
RU2664055C2 (ru) 2018-08-14
LTPA2022008I1 (hu) 2022-05-25
BR112014030577B1 (pt) 2022-02-08
IL236110A (en) 2016-11-30
IL236110A0 (en) 2015-01-29
CN104902895A (zh) 2015-09-09
ES2797252T3 (es) 2020-12-01
LUC00253I2 (hu) 2025-03-04
PH12014502757A1 (en) 2015-03-02
PH12018502294A1 (en) 2020-11-04
EP3722296A2 (en) 2020-10-14
LT3366293T (lt) 2020-07-10
AU2012327210B2 (en) 2016-07-28
CA2875970A1 (en) 2013-12-12
MX372814B (es) 2025-03-04
EP3722296A3 (en) 2020-10-21
EP2858646A4 (en) 2015-09-02
WO2013184119A1 (en) 2013-12-12
PH12014502757B1 (en) 2015-03-02
JP5883195B2 (ja) 2016-03-09
RS60406B1 (sr) 2020-07-31
CN110433162A (zh) 2019-11-12
AU2012327210A1 (en) 2014-01-09
MX2020005712A (es) 2022-05-17
DK2858646T3 (en) 2018-03-19
EP2858646B1 (en) 2017-12-20
HUE049958T2 (hu) 2020-11-30
EP3366293A1 (en) 2018-08-29
CN104902895B (zh) 2019-03-29
JP2015520186A (ja) 2015-07-16
BR112014030577A8 (pt) 2018-10-23
KR101652229B1 (ko) 2016-08-30
CY1123377T1 (el) 2021-12-31
KR20150053894A (ko) 2015-05-19
PT3366293T (pt) 2020-06-18

Similar Documents

Publication Publication Date Title
HUS2200017I1 (hu) Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
AP3847A (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
HK1210174A1 (en) Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases
HK1199814A1 (en) Inhibition of adaptor associated kinase for the treatment of pain
EP2887805A4 (en) COMPOUNDS AND METHOD FOR TREATING BLOOD HIGH PRESSURE
IL235767A0 (en) Converted pyrrolidines as factor xia inhibitors for the treatment of thromboembolic diseases
HK1205500A1 (en) Kinase inhibitors for the treatment of cancer
AP2014007905A0 (en) Novel compounds for the treatment of dyslipidemia and related diseases
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
IL231448A0 (en) Phosphatidylinositol 3-kinase inhibitors for cancer treatment
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors
GB201206048D0 (en) Novel compounds and their use as kinase inhibitors